Access Tomorrow’s Treatments Today

Empowering patients with cutting-edge radiopharmaceutical therapies, close to home.

Search Active TrialsTalk To A Clinical Navigator

Clinical Trials That Put Patients First

At United Theranostics, clinical trials are more than research, they are care. By integrating advanced radiopharmaceutical therapies with patient-centric support, we deliver local access to life-changing treatments while ensuring excellence at every step.

  • Advanced Theranostic Therapies
  • Local Centers with Global Expertise
  • Trust, Transparency, and Compassion
  • Seamless Participation & Retention Programs

Explore Our Active Clinical Trials

225Ac-ABD147-101 | Lung & Neuroendocrine Cancer | Abdera Therapeutics

View Details


Title: Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy

Sponsor: Abdera Therapeutics Inc.

Description: The study has 2 parts, Phase 1a and Phase 1b. The goal of Phase 1a is to gather safety, PK and initial efficacy data for 225Ac-ABD147 to better understand best doses for patients with small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) of the lung following platinum-based chemotherapy. An initial group of patients will also be given an experimental imaging agent called 111In-ABD147 to help understand where ABD147 goes in the body. The goal of Phase 1b is to gather additional safety and efficacy data on 225Ac-ABD147 to determine the best dose and to understand how those doses affect the same types of patients’ cancers explored enrolled in Phase 1a.

Number of patients to be enrolled (study wide):  ~65

Patient Eligibility Criteria:
If you want to know more about the study, review the complete details on ClinicalTrials.gov

If you are interested in more information about this trial:
Please fill out this form.

AB001 | Prostate | ARTBIO

View Details


Title: Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (ARTISAN)

Sponsor: ARTBIO

Description: TThis is a Phase 1, open-label, multicentre study to evaluate the safety, recommended dose level, and treatment schedule of AB001 in patients with advanced PSMA positive mCRPC. AB001 is an alpha-radiation generating, 212Pb-labelled, PSMA-targeted small molecule RLT. Participants in this study must have received previous treatment with at least one ARPI. Participants must either not have received previous PSMA-targeted radiopharmaceutical treatment (177Lu-PSMA naïve) or participants must have had prior treatment with at least one dose of Lutetium-177 (177Lu)-PSMA therapy (177Lu-PSMA experienced). In addition, the study will evaluate the biodistribution, PK, and body clearance of AB001.

Number of patients to be enrolled (study wide):  ~60

Patient Eligibility Criteria:
If you want to know more about the study, review the complete details on ClinicalTrials.gov

If you are interested in more information about this trial:
Please fill out this form.

SAX101 | Lung | Ariceum Therapeutics

View Details

Title:Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) (SANTANA-225)

Sponsor: Ariceum Therapeutics GmbH

Description: This study aims to determine safety, tolerability, recommended phase 2 dose (RP2D), and preliminary antitumor activity of 225Ac-SSO110 with standard of care (SoC) therapy in patients with somatostatin receptor 2 expressing (SSTR2+) extensive-stage small cell lung cancer (ES-SCLC) and recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).

Number of patients to be enrolled (study wide): ~50

Patient Eligibility Criteria:
If you want to know more about the study, review the complete details on ClinicalTrials.gov

If you are interested in more information about this trial:
Please fill out this form.

CLR 125 | Breast | Cellectar

View Details

Title:A Phase 1b, Open-Label Parallel Study Evaluating CLR 125 in Patients with Relapsed or
Refractory Triple Negative Breast Cancer

Sponsor: Cellectar

Description:This is a Phase 1b, randomized, open-label, multi-center study assessing the safety and efficacy of CLR 125 in patients with advanced TNBC. Three dose levels will be assessed in parallel, with enrollment of patients in a 1:1:1 manner. Each arm will have a minimum of 15 evaluable patients. Depending on arm assignments, patients will receive between two and four cycles. A Cycle is defined as an 8-week period (57 days), with CLR 125 administrated on Days 1, 2, 8, and 9 of each Cycle. An expansion arm may be evaluated in a minimum of at least 15 patients following evaluation of the three dose levels by the data monitoring committee (DMC).

Number of patients to be enrolled (study wide): ~75

Patient Eligibility Criteria:
Details coming soon

If you are interested in more information about this trial:
Please fill out this form.

Copper-64 PSMA I&T | Prostate | Curium US LLC

View Details

Title: Phase 3, Multi-Center, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Staging Men With Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy With Pelvic Lymph Node Dissection

Sponsor: Curium US LLC

Description:This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.

Number of patients to be enrolled (study wide): ~323

Patient Eligibility Criteria:
If you want to know more about the study, review the complete details on ClinicalTrials.gov

If you are interested in more information about this trial:
Please fill out this form.

225Ac-PSMA-I&T | Prostate | Fusion Pharmaceuticals Inc

View Details

Title: FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) (AlphaBreak)

Sponsor: Fusion Pharmaceuticals Inc

Description: This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I&T). Patient population is adult participants with PSMA positive mCRPC who have had previous treatment with with 177Lu-PSMA-617 or another 177Lu-PSMA radioconjugate (RC). The purpose of the study is to determine the safety and tolerability, and recommended dose and regiment of FPI-2265.

Number of patients to be enrolled (study wide): ~100

Patient Eligibility Criteria:
If you want to know more about the study, review the complete details on ClinicalTrials.gov

If you are interested in more information about this trial:
Please fill out this form.

[111In]In-MC-760 | Esophageal, Breast, Lung & Prostate | Mariana Oncology

View Details

Title: A Phase 0 study of [111In]In-MC-760 in Patients with Solid Tumors that Commonly Express B7-H3.

Sponsor: Mariana Oncology

Description:A Phase 0, Open-label First-in-Human Study to Evaluate the Biodistribution, Safety,
Tolerability, Pharmacokinetics, and Radiation Dosimetry of [111In]In-MC-760 in Adult
Patients with Solid Tumors that Commonly Express B7-H3

Number of patients to be enrolled (study wide): ~14

Patient Eligibility Criteria:
Currently in Phase 0

If you are interested in more information about this trial:
Please fill out this form.

²¹²Pb-DOTAM-GRPR1| Prostate, Breast, Colorectal, Cervical, Melanoma & Lung | Orano Med LLC

View Details

Title: Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Sponsor: Orano Med LLC

Description: A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors

Number of patients to be enrolled (study wide): ~55

Patient Eligibility Criteria:
If you want to know more about the study, review the complete details on ClinicalTrials.gov

If you are interested in more information about this trial:
Please fill out this form.

RAD301 | Pancreatic Cancer, Lung, Esophageal, Cervical, Ovarian & Endometrial | Radiopharm Theranostics, Ltd

View Details

Title: Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer (RAD301)

Sponsor: Radiopharm Theranostics, Ltd

Description: This is a Phase 1a, open label, single dose, extended study of safety and biokinetics of RAD301 in healthy human volunteers and individuals with PDAC.

Number of patients to be enrolled (study wide): ~9

Patient Eligibility Criteria:
If you want to know more about the study, review the complete details on ClinicalTrials.gov

If you are interested in more information about this trial:
Please fill out this form.

68Ga-R11228 & 177Lu-R11228 | Breast | Radionetics Oncology

View Details

Title: A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer

Sponsor: Radionetics Oncology

Description:Part A is being conducted to test 68Ga-R11228, a new investigational product (IP) that has been designed to detect cancer lesions in the body and make them visible on a Positron Emission Tomography (PET) scan. Three dose levels of 68Ga-R11228 will be evaluated, with each patient receiving a single dose. Part B is being conducted to test 68Ga-R11228 and additionally 177Lu-R11228, which has been designed to treat patients who have cancer lesions with positive uptake on PET scan using 68Ga-R11228. Patients who qualify for 177Lu-R11228 treatment will receive up to 6 doses over approximately 36 weeks. Multiple 177Lu-R11228 dose levels will be evaluated in Part B.

Number of patients to be enrolled (study wide): ~62

Patient Eligibility Criteria:
If you want to know more about the study, review the complete details on ClinicalTrials.gov

If you are interested in more information about this trial:
Please fill out this form.

RYZ101 | Neuroendocrine| RayzeBio, Inc.

View Details

Title: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (ACTION-1)

Sponsor: RayzeBio, Inc.

Description: This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following treatment with Lutetium 177-labelled somatostatin analogue (177Lu-SSA) therapy, such as 177Lu-DOTATATE or 177Lu-DOTATOC (177Lu-DOTATATE/TOC), or 177Lu-high affinity [HA]-DOTATATE.

Number of patients to be enrolled (study wide): ~288

Patient Eligibility Criteria:
If you want to know more about the study, review the complete details on ClinicalTrials.gov

If you are interested in more information about this trial:
Please fill out this form.

89Zr-DFO-girentuximab | Renal Cell | Telix Pharmaceuticals (Innovations) Pty Limited

View Details

Title: 89Zr-DFO-girentuximab Expanded Access Program (EAP)

Sponsor:Telix Pharmaceuticals (Innovations) Pty Limited

Description: The purpose of this Expanded Access Program (EAP) is to enable the use of 89Zr-DFO-girentuximab with positron emission tomography/computed tomography (PET/CT) imaging to non-invasively detect carbonic anhydrase 9 (CAIX)-expressing clear cell renal cell carcinoma (ccRCC) in patients with renal masses as determined by conventional imaging.

Number of patients to be enrolled (study wide): TBD

Patient Eligibility Criteria:
If you want to know more about the study, review the complete details on ClinicalTrials.gov

If you are interested in more information about this trial:
Please fill out this form.

177Lu-TLX591 | Prostate | Telix Pharmaceuticals (Innovations) Pty Limited

View Details

Title: The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Sponsor:Telix Pharmaceuticals (Innovations) Pty Limited

Description: The purpose of this Expanded Access Program (EAP) is to enable the use of 89Zr-DFO-girentuximab with positron emission tomography/computed tomography (PET/CT) imaging to non-invasively detect carbonic anhydrase 9 (CAIX)-expressing clear cell renal cell carcinoma (ccRCC) in patients with renal masses as determined by conventional imaging.

Number of patients to be enrolled (study wide): ~430

Patient Eligibility Criteria:
If you want to know more about the study, review the complete details on ClinicalTrials.gov

If you are interested in more information about this trial:
Please fill out this form.

UPCOMING: LY4337713 | Fap Solid Tumors | Eli Lilly 

View Details

Title: A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy with LY4337713 in Adults with FAP-Positive Solid Tumors (FiREBOLT)

Sponsor:Eli Lilly

Description:. This study is evaluating an investigational radiopharmaceutical called LY4337713 in people with advanced or metastatic cancers that have high levels of a protein known as fibroblast activation protein (FAP). The goal is to understand the safety and side effects of LY4337713, as well as any early signs that it may help treat FAP-positive tumors. Researchers will also study how the drug moves through the bloodstream, how it is broken down, and how long it stays in the body. Each participant will be followed for approximately five years to collect long-term safety and outcome data.

Number of patients to be enrolled (study wide): ~241

Patient Eligibility Criteria:
If you want to know more about the study, review the complete details on ClinicalTrials.gov

If you are interested in more information about this trial:
Please fill out this form.

Why Join a Clinical Trial?

  • Access new treatments before they are widely available.
  • Receive expert care from top specialists.
  • Help advance future medicine for others.
See if You’re Eligible

From Application to Care – What to Expect

Submit Interest or Referral

Submit Interest or Referral

Start by expressing your interest or having your healthcare provider refer you to one of our trials. Our team will review your information and guide you on the next steps. It's quick and confidential.
Pre-screening & Eligibility Check
Pre-screening & Eligibility Check
We conduct a thorough review of your medical history and may request lab tests to determine your eligibility. This step ensures the trial is a good match for your specific type of cancer. Our goal is to prioritize your safety and the potential for benefit.
Enrollment & Onboarding
Enrollment & Onboarding
Once you're eligible, we'll walk you through the enrollment process, including any paperwork and consent forms. Our staff will explain the study in detail so you know what to expect. You'll have the opportunity to ask questions at every stage.
Treatment & Follow-up
Treatment & Follow-up
You will begin receiving the trial treatment under close medical supervision. Our care team monitors your progress closely, adjusting as needed and supporting your comfort throughout. Regular follow-up visits help us track results and ensure your well-being.
Continued Support & Care

Continued Support & Care

Even after your participation ends, we stay connected. We offer guidance, coordinate with your primary care team, and provide access to additional resources. Your long-term health and support remain our priority.

World-Class Care Teams at Your Side

Dr. Michael A. Morris, MD, MS, DABR, DABNM, DCI

Dr. Babak Saboury, MD, MPH, DABR, DABNM

Dr. Eliot Siegel, MD, FACR, FSIM, DABR

Dr. Munir Ghesani, MD, FACNM, FACR, FSNMMI

Dr. Olga Molchanova-Cook, MD, PhD

Powered by Precision and Compassion

  • Uni-Claude™ AI platform for centralized operations
  • Dosimetry expertise
  • Regulatory harmonization
  • First to deliver alpha dosimetry with Actinium-225

Frequently Asked Questions

B
C

What is a radiopharmaceutical clinical trial?


A radiopharmaceutical clinical trial studies new cancer treatments that use targeted radioactive medicines known as radiopharmaceuticals to find and treat cancer cells. These trials evaluate the safety and effectiveness of advanced therapies, often combining precise molecular imaging with treatment. United Theranostics specializes in these trials, offering patients access to the latest innovations in targeted cancer care.
B
C

Will I have to travel far?


United Theranostics operates clinics in the following locations to make participation as accessible as possible:

  • Glen Burnie, MD
  • Princeton, NJ
  • Las Cruces, NM

We match participants to the nearest clinic whenever possible. In some cases, travel may be necessary if a specific trial is only available at a certain location. Our team will work with you to minimize travel and support your participation throughout the process.

B
C

Are there costs to participate?

Most clinical trials cover the costs of study-related treatments and required tests. Additional support, such as insurance assistance and financial aid, is often available. Before enrolling, our team will review any potential costs and available resources with you, ensuring you have a clear understanding of what to expect.
For more information about patient support services, you can also contact us at (800) 898-2650.

Talk to Our Clinical Trial Navigators

Fill out the form to schedule your personalized consultation.

Name(Required)